PALISADE Phase 3 Program focused on PH94B’s potential as a rapid-onset, acute treatment of anxiety in adults with social anxiety disorder SOUTH SAN FRANCISCO, Calif. , Sept. 13, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing

SOUTH SAN FRANCISCO, Calif. , Sept. 08, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous

PALISADE Phase 3 Program to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan Additional potential NDA-enabling clinical studies expected to initiate in 2021 SOUTH SAN FRANCISCO, Calif., Aug.

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics  (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous

Ms. FitzPatrick, an internationally recognized corporate affairs executive, brings extensive healthcare consumer engagement, marketing and public relations expertise to the Company’s Board SOUTH SAN FRANCISCO, Calif., July 22, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc .

SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics  (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous

Ms. Rotunno brings extensive healthcare industry expertise as a leader and strategist as VistaGen advances late-stage development of its product candidates for anxiety and depression disorders SOUTH SAN FRANCISCO, Calif., July 07, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc .

PALISADE-1 Phase 3 trial underway to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) Management to host corporate update conference call and audio webcast today at 2:00 p.m. PT SOUTH SAN FRANCISCO, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- 

SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central